Enitociclib (Standard)

Overview

Enitociclib (Standard) is the analytical standard of Enitociclib ( HY-103019 ). This product is intended for research and analytical applications. Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor ( IC 50 =3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II . Enitociclib specifically depletes key short-lived proteins such as c-MYC , MCL-1 and induces tumor cell apoptosis . Enitociclib also interferes with the production of enhancer RNAs ( eRNA ) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib ( HY-10227 ), Lenalidomide ( HY-A0003 ), Pomalidomide ( HY-10984 ), Venetoclax ( HY-15531 ) and Paclitaxel ( HY-B0015 ), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma.

Application

Products | Products > Signaling Pathways > Others | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > Drug Isomer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-103019R
• CAS No.: 1610408-97-3
• Molecular Formula: C19H18F2N4O2S
• Molecular Weight: 404.43
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source